Robert Hazlett, pharmaceutical industry analyst for BMO, speaks about Big Pharma's forced slimdown.
"Everyone has taken their lumps across the board. These companies are not right-sized for the productivity that they're seeing from their labs."
"They're paring back and, as new opportunities unfold, the companies will be in much better position to capture better economics," he said.
But the worst may not be over.
"It may take some more pain before they get there," Hazlett said.
More at Reuters
No comments:
Post a Comment